Curcumin's Effect in Advanced and Metastatic Breast Cancer Patients Treated with First or Second-line Docetaxel: A Randomized Trial

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2024 Sep 17

PMID 39286738

Authors

Passildas Jahanmohan Judith

Bernadach Maureen

Pouget Melanie

Kwiatkowski Fabrice

Vanpraagh-Doreau Isabelle

Dubray-Longeras Pascale

Abrial Catherine

Nabholtz Jean-Marc

Cure Herve

Delecroix Valerie

Chollet Philippe

Mouret-Reynier Marie-Ange

Affiliations

Soon will be listed here.

Abstract

Background: In this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second-line treatment potentiated the objective response rate.

Patients/methods: A multicentre, randomized, open label, phase-II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel-curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time-to-progression, progression-free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy.

Results: In this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate ( = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time-to-progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression-free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance ( = 0.14).

Conclusion: In this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second-line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.

References

Kwiatkowski F, Girard M, Hacene K, Berlie J . [Sem: a suitable statistical software adaptated for research in oncology]. Bull Cancer. 2000; 87(10):715-21. View

Aggarwal B . Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther. 2008; 7(9):1436-40. DOI: 10.4161/cbt.7.9.6659. View

Aggarwal B, Kumar A, Bharti A . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-98. View

Saghatelyan T, Tananyan A, Janoyan N, Tadevosyan A, Petrosyan H, Hovhannisyan A . Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine. 2020; 70:153218. DOI: 10.1016/j.phymed.2020.153218. View

Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W . Efficacy and Safety of Curcumin and Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Front Immunol. 2022; 13:891822. PMC: 9353077. DOI: 10.3389/fimmu.2022.891822. View

Azim Jr H, de Azambuja E, Colozza M, Bines J, Piccart M . Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011; 22(9):1939-1947. DOI: 10.1093/annonc/mdq683. View

Lao C, Ruffin 4th M, Normolle D, Heath D, Murray S, Bailey J . Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006; 6:10. PMC: 1434783. DOI: 10.1186/1472-6882-6-10. View

Sharma R, McLelland H, Hill K, Ireson C, Euden S, Manson M . Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001; 7(7):1894-900. View

Chainani-Wu N . Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003; 9(1):161-8. DOI: 10.1089/107555303321223035. View

10.

Sahu B, Hazarika H, Bharadwaj R, Loying P, Baishya R, Dash S . Curcumin-docetaxel co-loaded nanosuspension for enhanced anti-breast cancer activity. Expert Opin Drug Deliv. 2016; 13(8):1065-74. DOI: 10.1080/17425247.2016.1182486. View

11.

Chroni A, Mavromoustakos T, Pispas S . Curcumin-Loaded PnBA--POEGA Nanoformulations: A Study of Drug-Polymer Interactions and Release Behavior. Int J Mol Sci. 2023; 24(5). PMC: 10003461. DOI: 10.3390/ijms24054621. View

12.

Nabholtz J, Chalabi N, Radosevic-Robin N, Dauplat M, Mouret-Reynier M, Van Praagh I . Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer. 2015; 138(9):2274-80. DOI: 10.1002/ijc.29952. View

13.

Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M . Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2019; 18(7):1553-1560.e1. DOI: 10.1016/j.cgh.2019.08.041. View

14.

Zhang H, Kim H, Liu C, Yu S, Wang J, Grizzle W . Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta. 2007; 1773(7):1116-23. PMC: 2577190. DOI: 10.1016/j.bbamcr.2007.04.015. View

15.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal B . Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267(1):133-64. DOI: 10.1016/j.canlet.2008.03.025. View

16.

Shankar T, Shantha N, Ramesh H, Murthy I, Murthy V . Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol. 1980; 18(1):73-5. View

17.

Yang K, Lin L, Tseng T, Wang S, Tsai T . Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853(1-2):183-9. DOI: 10.1016/j.jchromb.2007.03.010. View

18.

Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A . Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009; 27(11):1753-60. DOI: 10.1200/JCO.2007.15.8485. View

19.

Amekyeh H, Alkhader E, Sabra R, Billa N . Prospects of Curcumin Nanoformulations in Cancer Management. Molecules. 2022; 27(2). PMC: 8777756. DOI: 10.3390/molecules27020361. View

20.

Nelson K, Dahlin J, Bisson J, Graham J, Pauli G, Walters M . The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017; 60(5):1620-1637. PMC: 5346970. DOI: 10.1021/acs.jmedchem.6b00975. View